Study Shows Castle Biosciences’ DecisionDx-UM is Highly Effective at Predicting Metastatic Risk in Patients with Eye Cancer
Source: Business Wire, November 2015
FRIENDSWOOD, Texas–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new study results of the Company’s DecisionDx-UM gene expression profile test, verifying that the assay is highly effective at identifying uveal melanoma tumors at high risk of metastasis. The results also confirmed the technical reliability of the test, which successfully classified 97% of uveal melanomas submitted for testing in this case series.
The study titled, “Gene expression profiling test of uveal melanoma: Prognostic validation,” was presented on November 13, 2015 at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 46th Annual Fall Scientific Symposium by Hakan Demirci, M.D., Director of Ocular Oncology and Associate Professor of Ophthalmology and Visual Sciences at the University of Michigan Kellogg Eye Center. Clinical data were collected from 210 consecutively diagnosed uveal melanoma patients who received the DecisionDx-UM test and were managed at this center.